

**Reference Number:** FOI202223/159  
**From:** Private Individual  
**Date:** 05 July 2022  
**Subject:** Number of patients treated for a list of diseases with a list of treatments

Q In total, over the past 4 months, how many patients have been treated for the following  
1 diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

A Please note, the following data is for Admissions only, we cannot identify patients in an  
1 Outpatient setting who have the above diseases.

In period Jan – Jun 22 there were 368 admissions which equated to 115 patients.

DIAG_DESC	Total
Arthropathic psoriasis	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Hidradenitis suppurativa	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Juvenile arthritis with systemic onset	29
Juvenile arthritis, unspecified	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Juvenile polyarthritis (seronegative)	129
Juvenile rheumatoid arthritis	31
Pauciarticular juvenile arthritis	157
Psoriasis vulgaris	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Psoriasis, unspecified	10
<b>Grand Total</b>	<b>368</b>
This equates to 115 patients	

Q Of these five, how many of each received the following products:

- 2
- Adalimumab (Humira)
  - Adalimumab Biosimilar
  - Etanercept (Enbrel)
  - Etanercept Biosimilar
  - Infliximab (Remicade)
  - Infliximab biosimilar
  - Golimumab (Simponi)
  - Tofacitinib (Xeljanz)
  - Ustekinumab (Stelara)
  - Vedolizumab (Entyvio)

- k. Filgotinib (Jyseleca)
- l. Abatacept (Orencia)
- m. Baricitinib (Olmiant)
- n. Certolizumab Pegol (Cimzia)
- o. Rituximab (MabThera)
- p. Rituximab Biosimilar
- q. Tocilizumab (RoActemra)
- r. Sarilumab (Kevzara)
- s. Apremilast (Otezla)
- t. Secukinumab (Cosentyx)
- u. Isekizumab (Taltz)
- v. Guselkumab (Tremfya)
- w. Brodalumab (Kyntheum)
- x. Risankizumab (Skyrizi)
- y. Tildrakizumab (Ilumetri)
- z. Upadacitinib (Rinvoq)
- aa. Bimekizumab (Bimzelx)

A 2	DRUG	Total
	ABATACEPT (ORENCIA)	17
	ADALIMUMAB (AMGEVITA)	77
	ADALIMUMAB (HUMIRA)	34
	ETANERCEPT (BENEPALI)	29
	ETANERCEPT (ENBREL)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	TOCILIZUMAB	7
	USTEKINUMAB	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	Grand Total	170
	This equates to 38 patients	

Q Could you please provide the number of these patients that were treated within the gastro  
3 department (still split by disease and treatment).

A of 115 patients how many had Outpatient activity Jan - Jun 2022

3

SPECIALTY	Total
Gastroenterology	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Grand Total	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.

Q Over the same time period, how many patients for each of the five diseases (Rheumatoid  
4 arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- a. AxSPA
- b. PsA
- c. PsO

A  
4

DIAG_DESC	DRUG	Total
Arthropathic psoriasis	ADALIM UMAB (AMGE VITA)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Juvenile arthritis, unspecified	ADALIM UMAB (AMGE VITA)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Juvenile polyarthritis (seronegative)	ABATA CEPT (OREN CIA)	11
	ADALIM UMAB (AMGE VITA)	9
	ADALIM UMAB (HUMIR A)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	ETANE RCEPT (BENEP ALI)	29
	ETANE RCEPT (ENBRE L)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	TOCILI ZUMAB	7
Juvenile rheumatoid arthritis	ABATA CEPT (OREN CIA)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	ADALIM UMAB (AMGE VITA)	8
	ADALIM UMAB (HUMIR A)	9
	ETANE RCEPT (ENBRE L)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Pauciarticular juvenile arthritis	ABATA CEPT (OREN CIA)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	ADALIM	54

	UMAB (AMGE VITA)	
	ADALIM UMAB (HUMIR A)	24
Psoriasis vulgaris	USTEKI NUMAB	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Psoriasis, unspecified	ADALIM UMAB (AMGE VITA)	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
	USTEKI NUMAB	Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.
Grand Total		170

The Trust is unable to respond to all or specific elements of your request where the response would indicate five or less individuals. The Trust is withholding this information under Section 40 (Personal Information) of the Freedom of Information Act (FOIA) 2000 to reduce the risk of any individuals being identified. The Trust is of the view that disclosure of such information would significantly increase the risk of individuals being identified and as such would constitute a breach of their personal data.

The Trust has applied exemption Section 40(2) of the FOIA and is therefore withholding the information as disclosure which may identify an individual would breach their rights under the Data Protection Act 2018. The grounds for application of this exemption include:

- Any data relating to patients or staff is third party data, furthermore health data is classified as sensitive personal data within the Data Protection Act 2018. As such, Section 40 (2) of the FOIA applies along with the Trusts duty of confidentiality. Therefore under s.2 (3) (f) (ii) of the FOIA, there is an absolute exemption from disclosure on the grounds that it would contravene the First Data Protection Principle.
- The Trust has a duty under the Data Protection Act 2018 and specifically the First Data Protection Principle to ensure personal data regarding staff and patients is processed fairly and lawfully. Disclosure of such data which may identify an individual, either through the data alone or other data in conjunction with that data which may identify an individual would therefore breach this principle.
- The Data Protection Act 2018 defines sensitive personal data to include data relating to the "physical or mental health or condition" of a person. Any such information about specific individuals falls within this category and disclosure of such data including statistical data, with any potential likelihood of identification would breach the Data Protection Act 2018.